ARTV Artiva Biotherapeutics Inc.

Subscribe to $ARTV

Artiva Biotherapeutics Inc.

Subscribe to $ARTV

$ARTV

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

IPO Year: 2024

Exchange: NASDAQ

Recent Analyst Ratings for Artiva Biotherapeutics Inc.

Date	Price Target	Rating	Analyst
8/13/2024	$21.00	Buy	Jefferies
8/13/2024	$23.00	Overweight	Cantor Fitzgerald
8/13/2024		Buy	TD Cowen
8/13/2024	$18.00	Outperform	Wedbush
8/13/2024	$23.00	Buy	Needham

See more ratings

Artiva Biotherapeutics Inc. Press Releases

Fastest customizable press release news feed in the world

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial
11/12/24 4:05:00 PM ET
$ARTV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the fir
11/11/24 4:05:00 PM ET
$ARTV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
10/22/24 4:05:00 PM ET
$ALLO
$ARTV
$CDXS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Major Chemicals
Industrials
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT, in New York City, New York. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public
9/10/24 4:05:00 PM ET
$ARTV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indicationsTreated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune d
8/29/24 4:05:00 PM ET
$ARTV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Artiva Biotherapeutics Inc.

Recent Analyst Ratings for Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc.

Recent Analyst Ratings for Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc. Press Releases

Fastest customizable press release news feed in the world

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Moore Alison

SEC Form 3 filed by new insider Moore Alison

Chief Medical Officer Graef Thorsten was granted 20,000 shares (SEC Form 4)

SVP, Research and Development Raymon Heather was granted 10,000 shares (SEC Form 4)

Chief Tech Operations Officer Horan Christopher was granted 25,000 shares (SEC Form 4)

Chief Financial Officer Krishnamohan Neha was granted 50,000 shares (SEC Form 4)

COO, CLO, Secy, Compliance Off Bush Jennifer was granted 50,000 shares, increasing direct ownership by 219% to 72,799 units (SEC Form 4)

Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

Large owner Wellington Biomedical Innovation Master Investors (Cayman) I L.P. converted options into 145,089 shares and acquired $499,994 worth of shares (49,019 units at $10.20) (SEC Form 4)

Artiva Biotherapeutics Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

SEC Form SC 13D filed by Artiva Biotherapeutics Inc.

SEC Form SC 13D filed by Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

TD Cowen initiated coverage on Artiva Biotherapeutics

Wedbush initiated coverage on Artiva Biotherapeutics with a new price target

Needham initiated coverage on Artiva Biotherapeutics with a new price target

Artiva Biotherapeutics Inc. SEC Filings

SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 8-K filed by Artiva Biotherapeutics Inc.

SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form S-8 filed by Artiva Biotherapeutics Inc.

SEC Form 8-K filed by Artiva Biotherapeutics Inc.

SEC Form 424B4 filed by Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc. Leadership Updates

Live Leadership Updates

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

Large owner Gc Corp. converted options into 1,352,252 shares, acquired $5,614,417 worth of shares (550,433 units at $10.20) and bought $24,999,984 worth of shares (2,083,332 units at $12.00) (SEC Form 4)

Director Huh Yong-Jun bought $24,999,984 worth of shares (2,083,332 units at $12.00), converted options into 1,352,252 shares and acquired $5,614,417 worth of shares (550,433 units at $10.20) (SEC Form 4)